The chairman's seat had been empty for two years. In September 2024, Zeng Mingguang resigned. In October 2026, Peng Yulong's qualifications as chairman were approved. During this period, an 810 million yuan capital increase was completed, IFC and the Asian Development Bank became joint second-largest shareholders, premium income approached 8 billion yuan, and net assets rose to 3.539 billion yuan. The slowness of governance completion was embedded in the speed of capital structure transformation.
In the third quarter of 2026, single-quarter profit reversed course, and investment-side volatility penetrated the income statement—a lesson management needs to address head-on. The chairman's appointment resolves 'who signs,' but the next question is whether the underwriting side can gradually take the wheel of profit direction.
On October 30, the Guangdong Financial Regulatory Bureau approved Peng Yulong's qualifications as chairman of Fosun United Health. At that point, nearly two years had passed since he began acting in the role as a director. During his acting tenure, Fosun United Health accomplished two key things.
In September 2025, an 810 million yuan capital increase was approved, raising registered capital to 1.01085 billion yuan. IFC and the Asian Development Bank each took 10.43% stakes, while Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. (600196) increased its holding to 20.05%, becoming the single largest shareholder.
Full-year 2025 premium income reached 7.841 billion yuan with net profit of 139 million yuan, both record highs since inception. But third-quarter 2026 data introduced volatility. Quarterly insurance business revenue was 2.987 billion yuan, net profit was -241 million yuan, and investment yield was -0.73%.
Cumulative net profit for the first three quarters remained at 331 million yuan. Single-quarter losses coexisting with cumulative profits put profit-side volatility squarely on the table. The timing of Peng Yulong's formal arrival sits at the intersection of four factors: capital increase completed, cumulative profit still acceptable, single-quarter profit under pressure, and international shareholder governance expectations yet to be fulfilled.
The governance loop has been closed, but the operational loop has only just begun.
Chairman Appointment: Governance 'Closure' After Nearly Two Years of Acting
On October 30, the Guangdong Financial Regulatory Bureau issued an approval announcement confirming Peng Yulong's qualifications as chairman of Fosun United Health. With this, the company's top position has traversed nearly two years between vacancy and acting arrangements.
The approval itself was not unexpected. Looking at the timeline, it is more like a belated full stop. In September 2024, then-chairman Zeng Mingguang resigned for personal reasons and later transferred to lead Fosun Prudential. In early December of the same year, Peng Yulong was first approved as a director of Fosun United Health. By late December, the board approved his acting chairman duties, and by Q3 2025 his resume was updated to reflect this responsibility.
Peng Yulong's background is familiar to the industry. He currently serves as vice president of Fosun High Technology, previously held roles as president of Fosun Financial Services Group, co-president of Fosun's insurance segment, and supervisor at Fosun Prudential Life. Earlier in his career, he was a non-executive director at New China Life Insurance.
Peng Yulong: Currently director and chairman of Fosun United Health, vice president of Shanghai Fosun High Technology (Group); concurrently director of Zhejiang MYbank. Previously served as director of New China Life, executive director of Xingheng Insurance Agency, director of Chongqing Rural Commercial Bank, chairman of Zhejiang Shangmeng Payment, and supervisor of Fosun Prudential Life.
In short, he is not an external parachute but someone who has played multiple moves on Fosun's insurance chessboard. From Fosun United Health's perspective, what it needed was precisely someone who could understand the internal synergy logic of the Fosun ecosystem while completing governance procedures under the regulatory framework.
The nearly two-year 'acting period' meant that, to some extent, Fosun United Health spent considerable time waiting for the official starting gun on key personnel, capital, and business rhythm decisions. But the acting period was not a blank. Peng Yulong maintained architectural operations in his acting capacity, while Lai Xiaohui bore more frontline operational responsibilities as party secretary and president.
Notably, during the two years of chairman absence, Lai Xiaohui as general manager concurrently held the party secretary role, effectively serving as the top leader—a significant change in the company's history, as previously the party secretary and chairman roles were held by the same person.
Lai Xiaohui is 49 years old. He was appointed president in July 2023, previously serving as deputy party secretary and chief investment officer. By at least May 2025, he was publicly attending party-building activities and speaking under the title 'Secretary Lai Xiaohui of Fosun United Health Insurance.'
The transition from 'deputy secretary' to 'secretary' aligned with the timeline of former chairman Zeng Mingguang's resignation in September 2024 and roughly synchronized with the pace of Peng Yulong beginning his acting role.
Lai Xiaohui: Currently party secretary, president, and chief investment officer of Fosun United Health. Previously served as vice president, assistant president, general manager of the Shanghai branch of Fosun United Health, senior director of health insurance at Fosun Group Health Holdings, and deputy director of the life insurance department at China Continent Property Insurance.
Since 2024, the company's senior management team has undergone a series of notable adjustments. The current team consists of nine executives, with assistant presidents Liu Yi and He Gang and chief compliance officer Ge Xing all joining in 2025. Assistant president Yao Jing joined in Q3 2026. Other team members also adjusted their roles or responsibilities around 2024.
Li Ming: Currently party committee member, discipline inspection secretary, vice president, and chief human resources officer of Fosun United Health. Previously served as managing director of human resources at Fosun Group and executive director of human resources at Sino Insurance Brokers.
Wang Guotao: Currently party committee member, vice president, and board secretary of Fosun United Health. Previously served as assistant president, compliance officer, and chief risk officer at Fosun United Health, health insurance director at Fosun Group Health Holdings, and preparatory head of the marine insurance operations center at China Continent Property Insurance.
Zhang Ruizhang: Currently party committee member, assistant president, and chief actuary of Fosun United Health. Previously served as deputy general manager of the actuarial department at Lian Life Insurance.
Liu Yi: Currently assistant president and chief financial officer of Fosun United Health. Previously served as assistant general manager, chief actuary, and chief risk officer at Huatai Life Insurance, and compliance officer and chief risk officer at General Reinsurance Shanghai Branch.
He Gang: Currently party committee member and assistant president of Fosun United Health. Previously served as business director at Fosun United Health, director of bancassurance at Kunlun Health, general manager of the health industry development center, deputy general manager (presiding) of the Beijing branch, and deputy general manager of the Anhui branch at CCB Life.
Yao Jing: Currently assistant president of Fosun United Health. Previously served as product director at Fosun United Health, general manager and deputy general manager of the health insurance business unit at ICBC-AXA Life, and head of market planning at Trust Mutual Life.
Zhu Hongchuang: Currently party committee member, audit officer, and chief risk officer of Fosun United Health. Previously served as general manager of the Jiangsu branch at Fosun United Health, senior director of health insurance business at Fosun Group Health Holdings, and head of product actuarial at the accident and health insurance department of China Continent Property Insurance.
Ge Xing: Currently chief compliance officer and legal responsible person of Fosun United Health. Previously served as assistant general manager (presiding) of the legal compliance department and board office at Hongkang Life, legal responsible person, and senior manager of legal compliance and intellectual property at Taikang Online's legal compliance and risk management department.
It was precisely during Peng Yulong's acting chairmanship that Fosun United Health simultaneously advanced several matters requiring governance-level presence in both capital structure and business front. How these matters were advanced provides a footnote for understanding decision-making authority under acting status.
The most important matter occurred almost simultaneously with the start of the acting period: the company's strategic capital increase launched in parallel. In September 2025, Fosun United Health was formally approved to complete an 810 million yuan strategic capital increase, raising registered capital from 694.44 million yuan to 1.01085 billion yuan.
IFC and the Asian Development Bank each injected 270 million yuan for 10.43% stakes, tied as second-largest shareholders. FOSUN PHARMA (02196) simultaneously injected 270 million yuan for a 20.05% stake, becoming the single largest shareholder. The Fosun group's combined holding stands at approximately 29.94%.
IFC and ADB entering a Chinese professional health insurance company simultaneously was a first in China's insurance industry. Two international multilateral institutions taking tied second-largest shareholder positions and each nominating a director to the board is even more unusual in a financial subsidiary dominated by the Fosun group.
However, as of now, no director clearly corresponding to IFC or ADB nominations appears in Fosun United Health's publicly disclosed board list. The shareholder meeting review of this capital increase occurred in late March 2025, when the chairman's seat was still in transitional arrangements after Zeng Mingguang's resignation. The approval and equity change completion fell after Peng Yulong began acting.
In other words, the acting chairman inherited a capital restructuring already underway that required continued governance follow-through. New shareholders brought not just capital but institutionalized expectations for governance transparency, financial discipline, and risk management—expectations that would not disappear because of an 'acting' chairman but would enter a more substantive fulfillment period with the formal approval.
What Peng Yulong inherited was a situation where capital increase had already been initiated and innovation piloted during the acting period. Formal status means these unfinished threads need to be 'closed out' under his watch.
Beyond Personnel: Legacy Restricted Equity and New Shareholder Expectations Arrive Together
In the week Peng Yulong's chairmanship was approved, market attention was not entirely on the personnel appointment itself. According to Fosun United Health's Q3 2026 solvency report, shares held by shareholders Yihua Real Estate (97.5 million shares, 9.65%) and Dongyin Holdings (95 million shares, 9.4%) are subject to pledge or freeze conditions.
Notably, this is not a new problem emerging in 2026—public reports show that as early as 2024, these two shareholders' combined 38.5% equity was already under judicial freeze. Subsequent capital increases diluted the proportion of frozen equity, but the problem itself was never truly resolved.
This means that at the moment Peng Yulong formally took the chairman's seat, approximately 19% of Fosun United Health's shareholder register remained in a restricted-rights state. The governance challenge before Peng Yulong is therefore one layer more complex than his predecessor faced: he must find an operable balance among Fosun group's dominant logic, international shareholders' multilateral governance expectations, and shareholder-level uncertainty from Yihua Real Estate and Dongyin Holdings' combined 19% restricted equity.
Pulling the view back to the present, more urgent than legacy equity issues is the sudden reversal of the operating curve. In late October, the company's Q3 2026 solvency report was released: quarterly insurance business revenue of 2.987 billion yuan and net profit of -241 million yuan, turning from profit to loss year-over-year.
Yet in the first half of 2026, the company's net profit was still 572 million yuan—more than four times the full-year 2025 figure of 139 million yuan. Capital increase completed, business climbing, profit reversing, shareholder equity restricted... After the chairman's appointment, the real test has only just been issued.
Three Phases Over Ten Years: Capital Games and Leadership Lineup
In the nine years since Fosun United Health was founded, its top two positions have been relatively stable. Tracing the company's trajectory over the past decade, management changes and capital operations have been highly correlated. From the founding partnership of Chen Qiyu and Zeng Mingguang, to the 'general and commander' arrangement of Zeng Mingguang and Lai Xiaohui, to the new combination of Peng Yulong and Lai Xiaohui—Fosun United Health's top-two configuration has always been a barometer of capital game fluctuations.
Following this thread of interwoven capital and personnel, the company's development can be roughly divided into three phases, with its governance structure iterating toward final resolution.
Phase One: Founding Partnership and the 'Medical Plus Insurance' Foundation (2017–2021)
Fosun United Health was established in January 2017 as China's sixth professional health insurance company, with initial registered capital of 500 million yuan. Fosun Industrial Investment held 20% as the largest shareholder, with the remaining five shareholders all private capital. As an insurance license within the Fosun group's health ecosystem, it was endowed from birth with strategic roles as 'payer' and 'customer touchpoint.'
Chen Qiyu and Zeng Mingguang were Fosun United Health's first-generation top two. Chen Qiyu's career centered on pharmaceuticals and health industries, representing shareholder interests by providing ecosystem access and strategic coordinates. Zeng Mingguang came from a medical background and had deep insurance industry experience, responsible for converting Fosun's medical resources into specific products and premiums.
Chen Qiyu: Born April 1972. Currently executive director and co-CEO of Fosun International, non-executive director of Shanghai Fosun Pharmaceutical (Group), non-executive director of Shanghai Henlius Biotech, and non-executive director and vice chairman of Sinopharm Group. Previously served as director and chairman of Fosun United Health and director of Tianjin Pharmaceutical Group.
Zeng Mingguang: Born in 1966. Appointed director of Fosun Prudential in September 2024, and chairman in April 2025. Currently vice president of Fosun International, concurrently non-executive director of Shanghai Fosun Health Technology (Group) and Fosun United Health. Previously served as chairman, party secretary, and general manager of Fosun United Health, supervisor and general manager of the life insurance department at China Continent Insurance.
The strategic priority in this phase was scale and ecosystem positioning. Under Chen Qiyu's 'health ecosystem' blueprint, Fosun United Health integrated shareholder and external medical resources, launching the 'medical plus insurance' model. Zeng Mingguang led branch establishment, product launches, and initial e-commerce and individual insurance channel development.
The financial cost was four consecutive years of losses. From 2017 to 2020, cumulative losses exceeded 240 million yuan, and the 500 million yuan initial capital was continuously consumed during expansion. It was not until 2021, as premium scale crossed the 3.7 billion yuan threshold and the scale effects of early investment began to show, that the company achieved its first profit of 20 million yuan.
But alongside the turnaround, solvency alarms were sounding. The meager profits earned were far from sufficient to cover capital consumption from business expansion. Fosun United Health's capital structure did not become more comfortable with profitability—it became more strained.
Phase Two: C-ROSS Phase II and Capital Increase Stalemate (2021–2023)
In early 2022, the 'C-ROSS Phase II' framework officially took effect. New rules imposed strict limits on the proportion of 'future surplus from policies' counted as core capital while raising risk factors for long-term equity investments and other assets.
For Fosun United Health, this meant the numerator was significantly squeezed of water while the denominator was markedly elevated. Its core solvency ratio subsequently plummeted from around 143% at end-2021 to 54.57% in Q1 2023, just one step from the 50% regulatory red line.
Facing this pure capital crisis, Fosun United Health's path to 'finding money' was extraordinarily difficult. From 2018 to 2021, the company proposed multiple capital increase plans, all of which failed to materialize due to shareholder qualification restrictions, lengthy approval cycles, and other reasons. For short-term relief, major shareholders even had to resort to 'cash donations' (totaling 650 million yuan) to supplement actual capital, but this could never replace registered capital.
In May 2023, Fosun United Health's extraordinary shareholder meeting simultaneously reviewed and passed the 'Resolution on Capital Increase' and the 'Resolution on Nominating Zeng Mingguang as Chairman.' This procedural arrangement sent a clear signal: personnel change and capital increase were bundled governance actions.
Under the capital stalemate, Zeng Mingguang was promoted to chairman, and Vice President Lai Xiaohui—who had long overseen investment and was deeply familiar with the company's capital situation—took over as president. This adjustment was not about strategic pivot; its core intent was to demonstrate to regulators and shareholders a determination to solve problems, with the person who best understood operations and capital stabilizing the foundation to ensure business rhythm did not spiral out of control and compliance底线 was maintained before external capital could land.
Phase Three: Capital Breakthrough and Governance Closure (2024–2026)
The capital stalemate finally broke in 2024. In the first half of 2024, Fosun United Health completed its first round of capital increase, with Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. (600196) and local state capital entering. Solvency pressure eased, with Q4 2024 comprehensive solvency ratio at 173% and core solvency ratio at 117%.
In September 2025, a second, larger capital increase was approved, with the International Finance Corporation (IFC) and Asian Development Bank (ADB) joining. Fosun United Health's registered capital rose to 1.011 billion yuan, upgrading its shareholder structure from purely private capital to a hybrid array of 'Fosun group plus local state capital plus international multilateral institutions.'
The arrival of capital instantly unblocked Fosun United Health's meridians. In 2025, the company's insurance business revenue reached 7.841 billion yuan, net profit hit a historic high of 139 million yuan—an increase of over 230%—and solvency stabilized and recovered.
However, alongside the capital breakthrough, the governance layer experienced a lengthy transition. In September 2024, Zeng Mingguang transferred to lead Fosun Prudential Life as chairman, after which Peng Yulong acted as chairman. During this transition, Fosun United Health formed a special configuration: Peng Yulong 'set the course' at the capital and strategic level in an acting capacity, while Lai Xiaohui 'carried the frontline' in operations and execution.
Peng Yulong, leveraging his coordinating role in Fosun's insurance segment, acted as a stabilizing force at the capital and strategic level, deeply participating in advancing two consecutive rounds of critical capital increases and external communications, and playing a bridging role in group resource coordination. Lai Xiaohui, meanwhile, shouldered the dual burdens of president and chief investment officer, withstanding the pressure of rapid performance growth.
This pairing was efficient in favorable conditions, but it also meant the governance defense line always had an 'unclosed' gap—the acting role lacked long-term expectations, and the operational side was overly dependent on a single core.
With Peng Yulong formally taking office, Fosun United Health's long march of 'capital increase plus leadership change' has finally concluded. The capital structure has been renewed, and the governance architecture has finally completed its last piece.
For a company that has crossed the 7 billion yuan premium threshold and entered the ranks of mid-sized insurers, the past decade was a capital history of struggling for survival and expansion. With the governance architecture now closed, the 'new phase' of Peng Yulong and Lai Xiaohui working together has only just begun. With a solid capital foundation and stable power structure, what lies before management is how to break free from dependence on specific channels and truly validate whether the 'medical plus insurance' model can sustainably create high-value profits.
Good Times: Rapid Development, Dual Growth in Assets and Business Scale
Fosun United Health performed excellently in 2025: total assets, business scale, investment returns, and net profit all flourished, with many financial indicators achieving substantial growth and breakthroughs. In Q3 2026, the insurer's net assets, insurance business revenue, and net profit maintained their growth momentum.
On the asset side, since its founding, Fosun United Health's total assets have maintained a growth trajectory. In 2025, total assets leaped 43.29% from 16.794 billion yuan to 24.065 billion yuan, breaking through the 20 billion yuan mark in one stroke. In Q3 2026, this indicator continued growing to 28.502 billion yuan.
Net assets have soared: up 135% year-over-year in 2023, up 24.90% to 2.962 billion yuan in 2025, and further growing to 3.539 billion yuan in Q3 2026—a historic high.
In terms of net profit, the insurer's profits have generally fluctuated but shown good growth in recent years. In 2025, Fosun United Health's net profit broke through the 100 million yuan mark, growing 231.24% year-over-year to 139 million yuan. In the first three quarters of 2026, this indicator reached 331 million yuan, already exceeding the full-year 2025 level.
In terms of business scale, Fosun United Health has maintained continuous growth, performing excellently in 2025. This indicator grew 50.06% year-over-year from 5.226 billion yuan to 7.841 billion yuan, crossing the 6 billion and 7 billion yuan thresholds and approaching 8 billion yuan. In Q3 2026, this indicator further grew to 7.946 billion yuan.
In terms of investment returns, the insurer has achieved steady growth with excellent recent performance. After a 158.96% surge in 2024, investment returns grew 4.79% year-over-year to 854 million yuan in 2025, steadily approaching 1 billion yuan.
In terms of expenditures, the insurer has significantly compressed claims costs in recent years. In 2025, claims payments decreased 45% year-over-year to 672 million yuan. However, alongside substantial business scale expansion, handling fees and commissions grew 12% year-over-year to 831 million yuan, and business and management expenses also grew 28% year-over-year to 454 million yuan.
(Note: Fosun United Health was just established in 2017; the 1060.70% figure here is the Q4 2017 solvency ratio.)
In terms of solvency, the insurer's ratios have remained in a safe range after two rounds of capital increases. In Q3 2026, the core solvency ratio was 106.88% and the comprehensive solvency ratio was 151.43%.
Conclusion: Health Insurance Profits and the Underwriting Steering Wheel
Peng Yulong's formal approval has drawn a belated full stop to Fosun United Health's governance. But after the full stop comes a question management must answer head-on: when one quarter of negative investment returns can shave 40% off cumulative profits from the first three quarters, what exactly sustains the profit structure resilience of this professional health insurer with premiums approaching 8 billion yuan?
Q3 2026 data has already provided clues. Quarterly investment yield was -0.73%, comprehensive investment yield was -0.21%, and cumulative net profit fell from 572 million yuan in the first half to 331 million yuan. Related researchers interpret this as: when underwriting-side revenue is relatively stable, any investment-side fluctuation amplifies into net profit. This means current profit elasticity remains highly dependent on asset-side performance.
Full-year 2025 investment returns were 854 million yuan. The underwriting side's direct contribution to profit needs clearer decomposition and validation. This is not a challenge unique to Fosun United Health. In Q1 2026, four professional health insurers combined saw premium growth of 15.69%, but combined net profit fell 11.11% year-over-year—profit pressure on the earnings side is industry-wide.
The median claims ratio for short-term health insurance is below 40%, while the industry-recognized reasonable range is 50% to 80%. The claims structure itself signals that underwriting-side pricing and expense discipline need more refined cultivation.
Fosun United Health's channel structure points in the same direction: bancassurance, internet, and brokerage channels advancing on multiple fronts with high expansion efficiency, but the rigidity of handling fees behind every premium dollar compresses underwriting-side profit space.
The path Peng Yulong has walked on Fosun's insurance chessboard determines that he will most likely not choose the conservative route of shrinking for profit. At a business discussion meeting in late 2025, he proposed three guidelines—'stay true to the original aspiration,' 'walk on two legs, emphasizing platform and scale,' and 'enhance organizational planning and command system building capabilities'—pointing toward a path of optimizing structure amid expansion.
For this path to work, three things deserve priority action after the chairman formally takes office, more than 'continuing to grow premiums.'
First, transform 'medical plus insurance' from narrative into decomposable financial units. Lai Xiaohui's 'medical alliance' and 'medical companion' programs presented at the 2026 Full Lifecycle Health Innovation Development Forum wrote long-term health management into policy terms, connected digital platforms at top-tier hospitals like Ruijin Hospital, and saw product scale exceed 100 million yuan. This is a genuine differentiated asset.
But differentiation must withstand management scrutiny: for every yuan invested in health management, how much improvement in claims ratio or increase in renewal rate does it correspond to? Elevating health management from a business department's 'innovation highlight' to a financially trackable unit is the first step in subjecting the narrative to operational verification.
Second, bring IFC and ADB governance expectations onto the board agenda, not just high-level talks. The two multilateral institutions each hold 10.43% and each nominate one director, discussing aging, inclusive health insurance, long-term care, and chronic disease management. These topics highly overlap with Fosun United Health's 'full lifecycle' positioning. International shareholders bring not just capital but institutionalized expectations for governance transparency and risk discipline.
What Peng Yulong needs to do is convert these expectations into regular board-level review items, making them an external anchor for underwriting discipline rather than leaving them as cooperation visions in press releases.
Third, maintain the efficiency floor of board decision-making before the equity disposal path is clarified. Yihua Real Estate's 9.65% and Dongyin Holdings' 9.4% equity remain restricted, totaling approximately 19%. Capital increase dilution reduced the proportion, but the rights defect itself has not been eliminated. The initiative on this matter is not entirely with management, but what the chairman can push is: before the disposal path is clear, ensure that the exercise of these equity rights does not interfere with the board's review rhythm on operational matters.
Fosun United Health has already traversed structural iterations from 'private shareholders restricted—state capital entering—international institutions joining.' If there is another round of equity changes, it should be a rules-based clearing.
Most domestic professional health insurers have walked similar paths: relying on shareholder resources and scale in the startup phase, facing solvency and capital supplementation tests in the middle phase, and shifting to refined value and compliance operations in the later phase. Fosun United Health's introduction of industrial capital and international institutions through two rounds of capital increases is a typical example of this path.
The long-term value of health insurance depends on whether claims management, product innovation, and service networks can form a closed loop—this is precisely the question the entire industry is collectively answering.
Fosun United Health waited one year and ten months for a chairman, demonstrating that shareholders are willing to invest time in the completeness of governance procedures. But the market's patience with a mid-sized insurer approaching 8 billion yuan in premiums will not be equally generous. What Peng Yulong has caught is a plate with a much thicker capital foundation than three years ago—and also a plate with more visible profit volatility than three years ago.
Governance 'backfill' is complete. The operational 'baton pass'—making underwriting-side pricing discipline, expense discipline, and health management value verification gradually become more stable sources of profit—is what this company truly needs to prove in its next chapter.
Comments